Viyash Scientific
VIYASH · Pharma > Pharmaceuticals & Drugs · Chairman: Kamal K Sharma · MD: Manish Gupta · Listing date: March 11, 2016 · Employees: 1770 · Bangalore · http://www.sequent.in

Stock Price vs Company Growth
1d
0.8%
1w
3.7%
1m
15.8%
3m
10.5%
6m
6.1%
1y
31.6%
5y
3.7%
10y
1.4%
all
0.6%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 188 0.8%
188
239
Company Overview

Sales
2,126 Cr
Growth: 18.0%
Profit after Tax
76.8 Cr
Growth: -7.4%
Mid Cap
8,232 Cr
P/E: 79.5x
Industry P/E: 27.1x
Fundamentals

Sales (Cr) ₹ 2,126
Growth 18.0%
EBITDA 15.5%
P/S 3.9x
Dividend 0.0%
P/E 79.5x
Book Value ₹ 18.5
PEG Ratio 4.4x
ROE 10.4%
P/B 10.2x
Shareholding Pattern

Institutions
Infinity Holdings
5.91 %
Unit Trust Of India Investment Advisory Services Limited A/C Ascent India Fund Iii
3.35 %
Ashoka India Opportunities Fund
1.35 %
Sbi Healthcare Opportunities Fund
1.21 %
Mukul Mahavir Agrawal
1.05 %
Promoters
Ca Harbor Investments
53.02 %
Chayadeep Ventures Llp
0.27 %
Rajitha Gopalakrishnan
0.2 %
Sajitha Pillai
0.15 %
Vineetha Mohanakumar Pillai
0.12 %
Others
Increase    Decrease    No change
Company Profile Detailed

Sequent Scientific earlier known as P I Drugs & Pharmaceuticals is an integrated pharmaceutical company. Hon'ble High Court of Bombay approved the Scheme of Amalgamation of company with P I Drugs & Pharmaceuticals Ltd.
Investors (91)
Followers (7)